REQUEST A DEMO
Total
USD $0.00
View basket Checkout now
Search more companies

Reber Genetics Co., Ltd. (Taiwan, China)

Main Activities: Pharmaceutical and Medicine Manufacturing | Research and Development in the Physical, Engineering, and Life Sciences
Full name: Reber Genetics Co., Ltd. Profile Updated: August 26, 2024
Buy our report for this company USD 29.95 Most recent financial data: 2023 Available in: English & Chinese Download a sample report

Reber Genetics Co., Ltd. is mainly engaged in the development and manufacturing animal vaccine products. The company was founded in 2008 and is headquartered in New Taipei City, Taiwan.

Headquarters
13F., No. 160, Sec. 6, Minquan E. Rd., Neihu Dist
Taipei City; Taipei City;

Contact Details: Purchase the Reber Genetics Co., Ltd. report to view the information.

Website: http://www.reber.com.tw

Basic Information
Total Employees:
Purchase the Reber Genetics Co., Ltd. report to view the information.
Outstanding Shares:
Purchase the Reber Genetics Co., Ltd. report to view the information.
Financial Auditors:
Purchase the Reber Genetics Co., Ltd. report to view the information.
Incorporation Date:
April 18, 2008
Key Executives
Purchase this report to view the information.
Chairman
Ownership Details
Purchase this report to view the information.
10.54%
Purchase this report to view the information.
9.85%
Purchase this report to view the information.
4.48%
Purchase this report to view the information.
2.82%
Purchase this report to view the information.
0.7%
Subsidiaries
Reber Genetics (Cayman) Co., Ltd.
100%
Company Performance
Financial values in the chart are available after Reber Genetics Co., Ltd. report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency TWD. Absolute financial data is included in the purchased report.
Net sales revenue
16.57%▲
Total operating revenue
17.34%▲
Operating profit (EBIT)
39.06%▲
EBITDA
56.64%▲
Net Profit (Loss) for the Period
50.39%▲
Total assets
34.13%▲
Total equity
23.56%▲
Operating Profit Margin (ROS)
48.68%▲
Net Profit Margin
56.78%▲
Return on Equity (ROE)
6.64%▲
Debt to Equity Ratio
5.8%▲
Quick Ratio
-0.29%▼
Cash Ratio
-0.25%▼

To view more information, Request a demonstration of the EMIS service

USD 29.95
Buy this company report
Need ongoing access to company, industry or country information?
Request a demo